Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121484 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 439
- Enrollment target
NCT01121484 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 439 participants.
The verdict
NCT01121484, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 439 participants
- Enrollment target
Study Summary
A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder
Interventions
- DRUG placebo
- DRUG desvenlafaxine succinate sustained-release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121484
The ClinicalTrials.gov registry entry for NCT01121484 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01121484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121484 about?
NCT01121484 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)". A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder
What is the current status of trial NCT01121484?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 439 participants. The study started on 2010-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01121484?
The interventions under investigation include: placebo (DRUG), desvenlafaxine succinate sustained-release (DRUG).
Who is sponsoring clinical trial NCT01121484?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.